Varun Chawla, MD
Nephrology · Fremont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 23
- 6 carriers
- Office
- 1
- Since medical school
- 21 years
- Graduated 2005
Offices
1 location · West Coast Kidney · 56 clinicians in this group
Hospitals listed: 052571 · 552514 · 552698 · Highland Hospital · St Rose Hospital · Washington Hospital. That is not proof they admit you there this week.
Plans that list them
23 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chawla’s office at (510) 745-8187 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
23 of 23 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A118650 · Current
Licensed to practise in California · since 2011 · expires 2027-09-30 · The All-India Institute of Medical Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Nephrology
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Highland HospitalOakland, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Alameda Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.568, Oct 2024 – Sep 2025
- St Rose HospitalHayward, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency departmentPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 1 of 5 starsNo measure marked better or worse than the national rate
- Washington HospitalFremont, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Washington Hospital Healthcare SystemPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.188, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.164, Oct 2024 – Sep 2025
See every measure and the patient survey for Highland Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 5 the same, 1 worse of 6 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.568 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 487 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.7 to 1.42) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.35 (145.43 to 251.26) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 83 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.3 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.9 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 68 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 1,143 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.38) · 4,370 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,344 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.54 (0.29 to 4.79) · 689 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.07 (0.37 to 3.78) · 165 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.91 (0.34 to 3.48) · 681 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.62 (2.72 to 20.53) · 179 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.44 (1.37 to 9.5) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.97 (0.49 to 3.45) · 126 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.76 (0.07 to 1.44) · 3,387 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.519 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.682 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 51 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 141.8 · 59 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 27.6 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 35.3 · 253 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 243 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.2 to 7.7) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (9.7 to 18.5) · 64 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.4 (10.8 to 19.4) · 355 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 84 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,960 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
See every measure and the patient survey for St Rose Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 0 better, 5 the same, 0 worse of 5 measures. Readmissions: 0 better, 3 the same, 2 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 227 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.57 to 1.47) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 11 · 57 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.2 · 62 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 20.6 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.2 · 567 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.32 (0.09 to 0.54) · 1,834 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,870 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.71 (1.17 to 6.25) · 285 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.13 (0.4 to 3.87) · 124 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.23 (0.53 to 3.92) · 295 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.87 (1.85 to 21.89) · 123 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.19 (0.86 to 9.51) · 120 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.27) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.36 (0 to 1.39) · 1,264 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 97 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.751 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.563 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 84 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.3 · 120 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35 · 116 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 29.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.8 · 147 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 101 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.9 · 72 cases | None | Jul 2023 – Jun 2025 |
What patients said (389 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 60% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 64% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Washington Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.188 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.164 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.59 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.95 (139.54 to 246.36) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 164 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 199 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 661 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 174 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 2,550 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 6,970 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,108 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.82 (1.73 to 5.91) · 1,370 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.52 (0 to 3.17) · 589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.75 (0.25 to 3.25) · 1,315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.19 (5.83 to 20.56) · 600 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.91 (1.04 to 8.78) · 550 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 6,079 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 114 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.367 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 480 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 33.9 · 186 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.5 · 553 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 36.8 · 648 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 590 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.2 to 6.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 14.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 130 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 202 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.5) · 78 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 974 cases | No different | Jan 2024 – Dec 2024 |
What patients said (812 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$257,500
Medicare paid this office $257,500 for 492 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Dialysis services, 4 or more physician visits per month (20 years or older) | 32 | $71,042 | $310 |
| Return visit (30+ min) | 209 | $50,119 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 106 | $23,025 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 143 | $18,440 | $69 |
| Long return visit (40+ min) | 46 | $12,054 | $167 |
See all 15 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 32 | $71,042 | $310 |
| Return visit (30+ min) | 209 | $50,119 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 106 | $23,025 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 143 | $18,440 | $69 |
| Long return visit (40+ min) | 46 | $12,054 | $167 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 72 | $11,174 | $149 |
| Telephone medical discussion with physician, 21-30 minutes | 54 | $9,095 | $114 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 231 | $8,050 | $14 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 32 | $7,814 | $59 |
| New patient visit (45+ min) | 31 | $4,321 | $139 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 32 | $3,956 | $46 |
| Hemodialysis procedure with physician evaluation | 33 | $2,877 | $63 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,168 | $114 |
| Advance care planning, first 30 minutes | 11 | $742 | $67 |
| Injection of drug or substance under skin or into muscle | 12 | $382 | $13 |
Who their Medicare patients are
492 Original Medicare patients in 2024. Average age 76 · Under 65 11% · 85 and older 22% · Women 46% · Also on Medicaid 64% · Health risk score 3.85. At or below the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Diabetes 75% · Chronic kidney disease 75% · Coronary heart disease 55% · Heart failure 50% · Atrial fibrillation 33% · COPD 25% · Dementia 23% · Cancer 19% · Depression 17% · Stroke 17%.
The office billed $691,818, Medicare allowed $338,001 and paid $257,500; for 2,510 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 492 | 2,510 | 76 | 3.85 | $691,818 | $257,500 |
| 2023 | 492 | 1,734 | 76 | 3.75 | $592,157 | $222,848 |
| 2022 | 501 | 1,767 | 75 | 3.67 | $561,578 | $202,132 |
| 2021 | 406 | 1,943 | 75 | 3.87 | $644,312 | $256,706 |
| 2020 | 413 | 2,021 | 75 | 3.91 | $629,800 | $242,072 |
| 2019 | 456 | 2,170 | 75 | 3.77 | $657,904 | $249,986 |
| 2018 | 459 | 1,927 | 75 | 3.62 | $578,796 | $219,279 |
| 2017 | 510 | 1,997 | 74 | 4.02 | $598,141 | $227,890 |
| 2016 | 489 | 1,863 | 74 | 4.17 | $549,759 | $225,444 |
| 2015 | 494 | 1,699 | 73 | 4.22 | $436,931 | $184,132 |
| 2014 | 418 | 1,695 | 73 | 4.35 | $420,092 | $184,100 |
| 2013 | 545 | 2,076 | 74 | 4.87 | $448,924 | $200,699 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 30 | $66,557 | $320 |
| Return visit (30+ min) | 205 | $45,363 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 170 | $27,420 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 99 | $21,838 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 73 | $12,745 | $157 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 50 | $6,002 | $118 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 16 | $5,424 | $271 |
| Long return visit (40+ min) | 28 | $4,995 | $116 |
| New patient visit (45+ min) | 31 | $4,454 | $144 |
| Telephone medical discussion with physician, 21-30 minutes | 33 | $4,190 | $95 |
| Hemodialysis procedure with physician evaluation | 40 | $3,164 | $65 |
2022: 11 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 25 | $40,916 | $320 |
| Return visit (30+ min) | 195 | $40,648 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 197 | $27,270 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 140 | $25,724 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 82 | $15,319 | $174 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 17 | $9,405 | $269 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 51 | $6,231 | $120 |
| New patient visit (45+ min) | 47 | $6,131 | $130 |
| Long return visit (40+ min) | 23 | $4,738 | $128 |
| Hemodialysis procedure with physician evaluation | 32 | $3,437 | $65 |
| Telephone medical discussion with physician, 21-30 minutes | 19 | $1,742 | $62 |
2021: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 32 | $65,476 | $323 |
| Return visit (30+ min) | 162 | $41,843 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 140 | $32,273 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 105 | $27,260 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 89 | $17,718 | $179 |
| Long return visit (40+ min) | 54 | $13,297 | $162 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 19 | $11,095 | $277 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 40 | $5,261 | $122 |
| Hemodialysis procedure with physician evaluation | 36 | $4,877 | $66 |
| New patient visit (60+ min) | 18 | $3,235 | $180 |
| New patient visit (45+ min) | 21 | $2,838 | $135 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $2,638 | $115 |
| Injection of drug or substance under skin or into muscle | 11 | $264 | $13 |
2020: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 37 | $81,617 | $261 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 160 | $39,629 | $66 |
| Return visit (30+ min) | 153 | $27,794 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 104 | $22,375 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 70 | $13,737 | $178 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 18 | $7,023 | $219 |
| Hemodialysis procedure with physician evaluation | 34 | $6,203 | $64 |
| Long return visit (40+ min) | 35 | $5,874 | $122 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 41 | $5,646 | $125 |
| New patient visit (45+ min) | 15 | $2,241 | $149 |
| Telephone medical discussion with physician, 21-30 minutes | 19 | $2,075 | $104 |
| Telephone medical discussion with physician, 11-20 minutes | 19 | $1,311 | $69 |
| Short return visit (20+ min) | 21 | $1,157 | $53 |
2019: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 41 | $77,812 | $257 |
| Return visit (30+ min) | 189 | $42,165 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 164 | $34,273 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 129 | $29,268 | $92 |
| Long return visit (40+ min) | 57 | $13,717 | $131 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 89 | $12,422 | $119 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 62 | $12,211 | $180 |
| Hemodialysis procedure with physician evaluation | 43 | $6,300 | $64 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 19 | $5,848 | $217 |
| New patient visit (45+ min) | 27 | $3,143 | $116 |
| New patient visit (60+ min) | 15 | $2,548 | $170 |
| Short return visit (20+ min) | 12 | $768 | $59 |
| Injection of drug or substance under skin or into muscle | 11 | $243 | $16 |
2018: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 34 | $73,395 | $254 |
| Return visit (30+ min) | 160 | $40,853 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 188 | $29,265 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 126 | $26,316 | $92 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 118 | $16,531 | $119 |
| Hemodialysis procedure with physician evaluation | 44 | $4,908 | $63 |
| Long return visit (40+ min) | 24 | $4,803 | $126 |
| New patient visit (45+ min) | 33 | $4,778 | $145 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 12 | $3,666 | $216 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,421 | $180 |
| Short return visit (20+ min) | 15 | $854 | $47 |
| Injection of drug or substance under skin or into muscle | 11 | $607 | $20 |
2017: 11 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 42 | $78,184 | $249 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 232 | $33,593 | $63 |
| Return visit (30+ min) | 145 | $32,459 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 138 | $27,207 | $91 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 98 | $12,638 | $119 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $9,915 | $174 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 26 | $8,460 | $212 |
| Hemodialysis procedure with physician evaluation | 50 | $6,293 | $62 |
| Long return visit (40+ min) | 31 | $5,368 | $122 |
| New patient visit (45+ min) | 24 | $2,971 | $124 |
| Dialysis procedure including 1 evaluation | 12 | $2,052 | $76 |
2016: 9 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 44 | $79,335 | $244 |
| Return visit (30+ min) | 140 | $31,528 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 140 | $28,259 | $171 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 135 | $26,594 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 207 | $24,917 | $62 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 25 | $8,985 | $204 |
| Long return visit (40+ min) | 28 | $5,408 | $113 |
| New patient visit (45+ min) | 41 | $5,306 | $129 |
| Hemodialysis procedure with physician evaluation | 44 | $4,246 | $62 |
2015: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 41 | $57,256 | $248 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 232 | $32,333 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 134 | $25,656 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 116 | $20,722 | $88 |
| Return visit (30+ min) | 99 | $16,939 | $90 |
| New patient visit (45+ min) | 45 | $6,363 | $141 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 12 | $5,436 | $209 |
| Hemodialysis procedure with physician evaluation | 43 | $4,050 | $62 |
| Long return visit (40+ min) | 20 | $3,495 | $129 |
| Critical care, first 30-74 minutes | 11 | $2,656 | $190 |
| Short return visit (20+ min) | 34 | $2,365 | $55 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,293 | $118 |
2014: 11 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 22 | $46,554 | $248 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 182 | $40,359 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 206 | $33,828 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 129 | $27,462 | $174 |
| Return visit (30+ min) | 66 | $11,636 | $93 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 14 | $5,642 | $209 |
| New patient visit (45+ min) | 25 | $3,504 | $140 |
| Long return visit (40+ min) | 18 | $2,939 | $128 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,706 | $118 |
| Short return visit (20+ min) | 29 | $2,108 | $62 |
| Hemodialysis procedure with physician evaluation | 23 | $1,936 | $62 |
2013: 9 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 25 | $49,182 | $245 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 224 | $47,544 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 316 | $47,348 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 126 | $23,238 | $170 |
| Hemodialysis procedure with physician evaluation | 78 | $8,135 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 57 | $6,906 | $115 |
| Short return visit (20+ min) | 39 | $4,401 | $62 |
| Return visit (30+ min) | 26 | $3,447 | $96 |
| New patient visit (30+ min) | 22 | $2,132 | $97 |
Medicaid work
$97,438 in 2024
Medicaid paid $97,438 for 1,067 billed services this clinician did in 2024, up to 42 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 231 | $42,245 |
| Return visit (30+ min) | 335 | $26,079 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 197 | $12,415 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 246 | $11,003 |
| Long return visit (40+ min) | 43 | $4,342 |
| 1ST HOSP IP/OBS HIGH 75 | 15 | $1,353 |
| 2024 | 1,067 | 6 | 42 | $97,438 |
| 2023 | 1,284 | 6 | 45 | $110,634 |
| 2022 | 1,194 | 5 | 53 | $80,852 |
| 2021 | 1,309 | 6 | 49 | $95,826 |
| 2020 | 1,345 | 5 | 44 | $67,986 |
| 2019 | 1,477 | 6 | 65 | $70,413 |
| 2018 | 1,512 | 5 | 60 | $72,653 |
See the largest Medicaid services in earlier years
2023
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 273 | $51,805 |
| Return visit (30+ min) | 377 | $31,518 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 420 | $13,076 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 184 | $11,210 |
| Long return visit (40+ min) | 17 | $2,121 |
| 1ST HOSP IP/OBS HIGH 75 | 13 | $904 |
2022
| Return visit (30+ min) | 449 | $33,394 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 176 | $32,514 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 216 | $7,501 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 336 | $6,796 |
| 1ST HOSP IP/OBS HIGH 75 | 17 | $647 |
2021
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 287 | $46,189 |
| Return visit (30+ min) | 457 | $32,121 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 378 | $6,544 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 133 | $5,747 |
| Long return visit (40+ min) | 41 | $4,432 |
| 1ST HOSP IP/OBS HIGH 75 | 13 | $793 |
2020
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 344 | $34,847 |
| Return visit (30+ min) | 355 | $19,070 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 167 | $6,546 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 463 | $6,043 |
| Long return visit (40+ min) | 16 | $1,480 |
2019
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 326 | $27,248 |
| Return visit (30+ min) | 484 | $22,912 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 200 | $7,569 |
| Long return visit (40+ min) | 101 | $6,422 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 341 | $6,163 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 25 | $99 |
2018
| Return visit (30+ min) | 532 | $29,014 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 352 | $28,604 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 233 | $8,023 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 380 | $6,728 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 15 | $283 |
Drugs they prescribed that Part D paid
$827,407
Pharmacies billed $827,407 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,992) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
1,421 generic and fewer than 11 brand-name prescriptions · $827,407 in drug cost · 23 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Farxiga | 177 | $213,930 | $1,209 |
| Lokelma | 146 | $195,419 | $1,338 |
| Xphozah | 29 | $84,604 | $2,917 |
| Rayaldee | 54 | $67,326 | $1,247 |
| Kerendia | 49 | $66,024 | $1,347 |
See all 31 drugs
| Farxiga | 177 | $213,930 | $1,209 |
| Lokelma | 146 | $195,419 | $1,338 |
| Xphozah | 29 | $84,604 | $2,917 |
| Rayaldee | 54 | $67,326 | $1,247 |
| Kerendia | 49 | $66,024 | $1,347 |
| Veltassa | 21 | $27,136 | $1,292 |
| Sevelamer Carbonate | 72 | $26,437 | $367 |
| Procrit | 13 | $13,243 | $1,019 |
| Dapagliflozin | 12 | $9,097 | $758 |
| Cinacalcet | 15 | $7,517 | $501 |
| Calcitriol | 365 | $7,436 | $20 |
| Retacrit | 14 | $4,718 | $337 |
| Calcium Acetate | 49 | $4,627 | $94 |
| Losartan | 131 | $1,197 | $9 |
| Hydralazine | 94 | $1,161 | $12 |
| Bumetanide | 23 | $1,048 | $46 |
| Valsartan | 13 | $991 | $76 |
| Carvedilol | 103 | $705 | $7 |
| Nifedipine Er | 15 | $693 | $46 |
| Amlodipine Besylate | 105 | $555 | $5 |
| Furosemide | 47 | $480 | $10 |
| Allopurinol | 43 | $479 | $11 |
| Vitamin D2 | 24 | $442 | $18 |
| Metoprolol | 26 | $359 | $14 |
| Midodrine | 11 | $250 | $23 |
| Atorvastatin | 14 | $187 | $13 |
| Spironolactone | 12 | $141 | $12 |
| Potassium Chloride | 13 | $131 | $10 |
| Clonidine | 15 | $104 | $7 |
| Lisinopril | 29 | $104 | $4 |
| Hydrochlorothiazide | 16 | $68 | $4 |
Year by year
| 2024 | 1,992 | 278 | 0% (0) | None | $827,407 |
| 2023 | 1,776 | 256 | 0% (0) | None | $774,046 |
| 2022 | 1,543 | 242 | 0% (0) | 22% | $669,293 |
| 2021 | 1,497 | 210 | 0% (0) | 26% | $470,748 |
| 2020 | 1,641 | 206 | None | None | $486,364 |
| 2019 | 1,717 | 190 | 0% (0) | 22% | $341,611 |
| 2018 | 1,798 | 178 | 0% (0) | None | $472,690 |
| 2017 | 1,831 | 149 | 0% (0) | None | $777,873 |
| 2016 | 1,648 | 144 | 0% (0) | 30% | $567,116 |
| 2015 | 1,083 | 120 | 0% (0) | None | $231,910 |
| 2014 | 794 | 72 | None | 34% | $155,075 |
| 2013 | 317 | 40 | 0% (0) | 36% | $58,148 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 27 drugs
| Farxiga | 132 | $219,494 | $1,663 |
| Lokelma | 117 | $175,906 | $1,503 |
| Kerendia | 50 | $65,781 | $1,316 |
| Renvela | 17 | $37,303 | $2,194 |
| Rayaldee | 29 | $36,593 | $1,262 |
| Sevelamer Carbonate | 55 | $24,797 | $451 |
| Veltassa | 15 | $22,022 | $1,468 |
| Cinacalcet | 13 | $20,120 | $1,548 |
| Procrit | 23 | $15,155 | $659 |
| Calcitriol | 310 | $9,474 | $31 |
| Calcium Acetate | 54 | $5,534 | $102 |
| Hydralazine | 138 | $3,866 | $28 |
| Losartan | 117 | $2,598 | $22 |
| Amlodipine Besylate | 124 | $1,958 | $16 |
| Carvedilol | 76 | $1,648 | $22 |
| Nifedipine Er | 21 | $1,053 | $50 |
| Allopurinol | 49 | $988 | $20 |
| Bumetanide | 18 | $899 | $50 |
| Atorvastatin | 19 | $541 | $28 |
| Furosemide | 54 | $527 | $10 |
| Lisinopril | 34 | $322 | $9 |
| Metoprolol | 18 | $293 | $16 |
| Potassium Chloride | 13 | $287 | $22 |
| Prednisone | 12 | $138 | $11 |
| Vitamin D2 | 24 | $113 | $5 |
| Atenolol | 11 | $99 | $9 |
| Ciprofloxacin | 11 | $73 | $7 |
2022: 28 drugs
| Tavneos | 12 | $183,116 | $15,260 |
| Lokelma | 93 | $118,710 | $1,276 |
| Farxiga | 69 | $106,745 | $1,547 |
| Renvela | 28 | $60,730 | $2,169 |
| Rayaldee | 31 | $40,691 | $1,313 |
| Sevelamer Carbonate | 54 | $34,112 | $632 |
| Veltassa | 18 | $30,332 | $1,685 |
| Kerendia | 23 | $22,968 | $999 |
| Calcitriol | 248 | $6,605 | $27 |
| Procrit | 12 | $6,169 | $514 |
| Calcium Acetate | 37 | $5,499 | $149 |
| Hydralazine | 136 | $2,713 | $20 |
| Amlodipine Besylate | 134 | $1,519 | $11 |
| Nifedipine Er | 15 | $1,422 | $95 |
| Carvedilol | 56 | $1,209 | $22 |
| Losartan | 83 | $956 | $12 |
| Potassium Chloride | 24 | $926 | $39 |
| Valsartan | 16 | $890 | $56 |
| Bumetanide | 11 | $816 | $74 |
| Allopurinol | 43 | $725 | $17 |
| Metoprolol | 11 | $645 | $59 |
| Furosemide | 52 | $506 | $10 |
| Lisinopril | 54 | $435 | $8 |
| Minoxidil | 20 | $332 | $17 |
| Atenolol | 13 | $250 | $19 |
| Metoprolol | 13 | $240 | $18 |
| Vitamin D2 | 15 | $73 | $5 |
| Ciprofloxacin | 19 | $63 | $3 |
2021: 28 drugs
| Lokelma | 86 | $82,302 | $957 |
| Rayaldee | 57 | $69,092 | $1,212 |
| Renvela | 23 | $57,899 | $2,517 |
| Veltassa | 48 | $52,837 | $1,101 |
| Velphoro | 14 | $40,726 | $2,909 |
| Sevelamer Carbonate | 55 | $20,936 | $381 |
| Farxiga | 23 | $18,524 | $805 |
| Auryxia | 13 | $15,347 | $1,181 |
| Retacrit | 28 | $7,705 | $275 |
| Calcium Acetate | 55 | $7,341 | $133 |
| Calcitriol | 185 | $6,464 | $35 |
| Hydralazine | 121 | $3,134 | $26 |
| Prosol | 28 | $3,087 | $110 |
| Amlodipine Besylate | 153 | $1,546 | $10 |
| Potassium Chloride | 29 | $1,112 | $38 |
| Carvedilol | 70 | $1,073 | $15 |
| Losartan | 42 | $795 | $19 |
| Nifedipine Er | 11 | $779 | $71 |
| Allopurinol | 49 | $774 | $16 |
| Furosemide | 57 | $543 | $10 |
| Midodrine | 14 | $501 | $36 |
| Minoxidil | 11 | $469 | $43 |
| Lisinopril | 46 | $419 | $9 |
| Atorvastatin | 13 | $200 | $15 |
| Clonidine | 15 | $172 | $11 |
| Prednisone | 12 | $139 | $12 |
| Vitamin D2 | 16 | $92 | $6 |
| Hydrochlorothiazide | 11 | $91 | $8 |
2020: 31 drugs
| Renvela | 51 | $130,566 | $2,560 |
| Veltassa | 69 | $68,403 | $991 |
| Lokelma | 85 | $67,502 | $794 |
| Rayaldee | 53 | $59,689 | $1,126 |
| Velphoro | 14 | $45,109 | $3,222 |
| Sevelamer Carbonate | 54 | $35,397 | $656 |
| Procrit | 16 | $12,153 | $760 |
| Calcitriol | 224 | $6,562 | $29 |
| Prosol | 58 | $5,478 | $94 |
| Intralipid | 26 | $4,066 | $156 |
| Calcium Acetate | 42 | $3,964 | $94 |
| Retacrit | 14 | $3,843 | $275 |
| Hydralazine | 123 | $2,343 | $19 |
| Potassium Chloride | 20 | $1,063 | $53 |
| Carvedilol | 99 | $1,040 | $11 |
| Amlodipine Besylate | 109 | $931 | $9 |
| Allopurinol | 68 | $837 | $12 |
| Nifedipine Er | 12 | $828 | $69 |
| Eplerenone | 11 | $802 | $73 |
| Losartan | 55 | $555 | $10 |
| Gentamicin Sulfate | 13 | $534 | $41 |
| Midodrine | 25 | $530 | $21 |
| Furosemide | 46 | $485 | $11 |
| Lisinopril | 48 | $441 | $9 |
| Captopril | 12 | $371 | $31 |
| Atorvastatin | 24 | $327 | $14 |
| Pantoprazole | 14 | $251 | $18 |
| Clonidine | 21 | $219 | $10 |
| Glipizide | 12 | $141 | $12 |
| Metoprolol | 19 | $93 | $5 |
| Ciprofloxacin | 11 | $46 | $4 |
2019: 35 drugs
| Renvela | 54 | $106,613 | $1,974 |
| Veltassa | 61 | $57,750 | $947 |
| Rayaldee | 23 | $28,283 | $1,230 |
| Lokelma | 34 | $27,551 | $810 |
| Velphoro | 13 | $25,707 | $1,977 |
| Sevelamer Carbonate | 44 | $23,558 | $535 |
| Procrit | 21 | $9,005 | $429 |
| Prosol | 64 | $7,631 | $119 |
| Calcitriol | 250 | $6,398 | $26 |
| Retacrit | 12 | $3,379 | $282 |
| Hydralazine | 160 | $2,602 | $16 |
| Calcium Acetate | 32 | $2,224 | $70 |
| Nifedipine Er | 31 | $1,846 | $60 |
| Olmesartan Medoxomil | 24 | $1,304 | $54 |
| Labetalol | 14 | $1,253 | $90 |
| Allopurinol | 78 | $1,205 | $15 |
| Carvedilol | 90 | $1,198 | $13 |
| Metoprolol | 14 | $985 | $70 |
| Amlodipine Besylate | 106 | $715 | $7 |
| Bumetanide | 16 | $715 | $45 |
| Gentamicin Sulfate | 12 | $609 | $51 |
| Losartan | 73 | $528 | $7 |
| Potassium Chloride | 16 | $423 | $26 |
| Lisinopril | 40 | $374 | $9 |
| Captopril | 12 | $365 | $30 |
| Pantoprazole | 12 | $333 | $28 |
| Atorvastatin | 23 | $311 | $14 |
| Clonidine | 36 | $297 | $8 |
| Ranitidine | 14 | $292 | $21 |
| Furosemide | 49 | $245 | $5 |
| Prednisone | 22 | $215 | $10 |
| Metoprolol | 35 | $138 | $4 |
| Glipizide | 16 | $127 | $8 |
| Warfarin | 17 | $75 | $4 |
| Clopidogrel | 13 | $58 | $4 |
2018: 34 drugs
| Renvela | 94 | $182,679 | $1,943 |
| Velphoro | 54 | $119,411 | $2,211 |
| Veltassa | 30 | $37,290 | $1,243 |
| Sevelamer Carbonate | 42 | $36,400 | $867 |
| Procrit | 16 | $10,261 | $641 |
| Calcitriol | 284 | $4,933 | $17 |
| Calcium Acetate | 58 | $4,421 | $76 |
| Nifedipine Er | 58 | $2,609 | $45 |
| Hydralazine | 129 | $1,683 | $13 |
| Prosol | 14 | $1,658 | $118 |
| Potassium Citrate Er | 13 | $1,357 | $104 |
| Allopurinol | 82 | $1,036 | $13 |
| Metoprolol | 17 | $1,011 | $59 |
| Gentamicin Sulfate | 15 | $1,007 | $67 |
| Labetalol | 17 | $1,005 | $59 |
| Valsartan | 29 | $775 | $27 |
| Amlodipine Besylate | 122 | $480 | $4 |
| Carvedilol | 90 | $475 | $5 |
| Lisinopril | 70 | $461 | $7 |
| Losartan | 52 | $294 | $6 |
| Atorvastatin | 29 | $276 | $10 |
| Omeprazole | 26 | $238 | $9 |
| Pantoprazole | 27 | $199 | $7 |
| Glipizide | 24 | $192 | $8 |
| Clonidine | 35 | $191 | $5 |
| Metoprolol | 32 | $159 | $5 |
| Furosemide | 53 | $147 | $3 |
| Levothyroxine | 12 | $136 | $11 |
| Tamsulosin | 13 | $132 | $10 |
| Ciprofloxacin | 18 | $111 | $6 |
| Warfarin | 12 | $94 | $8 |
| Hydrochlorothiazide | 17 | $65 | $4 |
| Clopidogrel | 12 | $48 | $4 |
| Simvastatin | 13 | $45 | $3 |
2017: 37 drugs
| Renvela | 137 | $344,904 | $2,518 |
| Sensipar | 97 | $221,929 | $2,288 |
| Velphoro | 34 | $85,718 | $2,521 |
| Veltassa | 35 | $23,923 | $684 |
| Procrit | 11 | $14,199 | $1,291 |
| Calcium Acetate | 64 | $5,265 | $82 |
| Calcitriol | 238 | $3,985 | $17 |
| Lantus | 15 | $3,794 | $253 |
| Lantus Solostar | 11 | $3,154 | $287 |
| Novolog | 11 | $3,053 | $278 |
| Nifedipine Er | 52 | $2,577 | $50 |
| Hydralazine | 113 | $1,739 | $15 |
| Sps | 15 | $1,596 | $106 |
| Potassium Citrate Er | 13 | $1,405 | $108 |
| Gentamicin Sulfate | 11 | $835 | $76 |
| Valsartan | 23 | $818 | $36 |
| Amlodipine Besylate | 141 | $527 | $4 |
| Lisinopril | 66 | $447 | $7 |
| Carvedilol | 79 | $360 | $5 |
| Atorvastatin | 28 | $351 | $13 |
| Allopurinol | 30 | $338 | $11 |
| Losartan | 69 | $303 | $4 |
| Levetiracetam | 17 | $267 | $16 |
| Minoxidil | 14 | $257 | $18 |
| Omeprazole | 30 | $217 | $7 |
| Metoprolol | 40 | $213 | $5 |
| Pantoprazole | 24 | $201 | $8 |
| Levothyroxine | 15 | $159 | $11 |
| Clonidine | 34 | $148 | $4 |
| Glipizide | 14 | $92 | $7 |
| Simvastatin | 16 | $77 | $5 |
| Ciprofloxacin | 15 | $73 | $5 |
| Furosemide | 21 | $68 | $3 |
| Hydrochlorothiazide | 21 | $62 | $3 |
| Ranitidine | 12 | $56 | $5 |
| Clopidogrel | 13 | $49 | $4 |
| Atenolol | 14 | $36 | $3 |
2016: 36 drugs
| Renvela | 100 | $238,669 | $2,387 |
| Sensipar | 81 | $148,101 | $1,828 |
| Velphoro | 41 | $72,897 | $1,778 |
| Fosrenol | 19 | $27,869 | $1,467 |
| Nexium | 33 | $10,499 | $318 |
| Calcium Acetate | 96 | $6,573 | $68 |
| Lantus | 17 | $4,312 | $254 |
| Intralipid | 18 | $3,006 | $167 |
| Calcitriol | 165 | $2,816 | $17 |
| Benicar | 12 | $2,030 | $169 |
| Prosol | 16 | $1,842 | $115 |
| Nifedipine Er | 35 | $1,526 | $44 |
| Potassium Citrate Er | 13 | $1,452 | $112 |
| Hydralazine | 108 | $1,283 | $12 |
| Valsartan | 36 | $1,081 | $30 |
| Metoprolol | 25 | $610 | $24 |
| Amlodipine Besylate | 114 | $405 | $4 |
| Nifedical Xl | 15 | $326 | $22 |
| Insulin | 11 | $286 | $26 |
| Lisinopril | 64 | $251 | $4 |
| Allopurinol | 29 | $237 | $8 |
| Clonidine | 46 | $224 | $5 |
| Tamsulosin | 11 | $214 | $19 |
| Carvedilol | 53 | $203 | $4 |
| Pravastatin | 11 | $199 | $18 |
| Losartan | 30 | $185 | $6 |
| Pantoprazole | 24 | $174 | $7 |
| Metoprolol | 49 | $167 | $3 |
| Atorvastatin | 17 | $150 | $9 |
| Glipizide | 29 | $133 | $5 |
| Ranitidine | 14 | $114 | $8 |
| Omeprazole | 24 | $113 | $5 |
| Hydrochlorothiazide | 15 | $74 | $5 |
| Gabapentin | 13 | $65 | $5 |
| Furosemide | 27 | $41 | $2 |
| Atenolol | 13 | $23 | $2 |
2015: 24 drugs
| Renvela | 71 | $124,557 | $1,754 |
| Sensipar | 23 | $27,202 | $1,183 |
| Velphoro | 14 | $16,016 | $1,144 |
| Renagel | 12 | $10,797 | $900 |
| Calcium Acetate | 48 | $3,225 | $67 |
| Calcitriol | 150 | $2,413 | $16 |
| Potassium Citrate Er | 12 | $1,564 | $130 |
| Nifedipine Er | 46 | $1,252 | $27 |
| Valsartan | 11 | $725 | $66 |
| Hydralazine | 51 | $539 | $11 |
| Amlodipine Besylate | 103 | $441 | $4 |
| Lisinopril | 66 | $289 | $4 |
| Carvedilol | 48 | $254 | $5 |
| Pantoprazole | 12 | $235 | $20 |
| Furosemide | 69 | $174 | $3 |
| Hydrochlorothiazide | 28 | $139 | $5 |
| Metoprolol | 18 | $98 | $5 |
| Omeprazole | 16 | $95 | $6 |
| Losartan | 16 | $84 | $5 |
| Simvastatin | 14 | $70 | $5 |
| Atenolol | 18 | $60 | $3 |
| Ranitidine | 11 | $59 | $5 |
| Famotidine | 12 | $59 | $5 |
| Spironolactone | 11 | $27 | $2 |
2014: 19 drugs
| Renvela | 75 | $94,437 | $1,259 |
| Diovan | 26 | $6,353 | $244 |
| Januvia | 12 | $3,574 | $298 |
| Calcium Acetate | 29 | $2,831 | $98 |
| Prosol | 17 | $2,766 | $163 |
| Benicar | 16 | $1,917 | $120 |
| Calcitriol | 61 | $1,005 | $16 |
| Nifedipine Er | 21 | $657 | $31 |
| Midodrine | 18 | $582 | $32 |
| Amlodipine Besylate | 96 | $517 | $5 |
| Hydralazine | 37 | $428 | $12 |
| Lisinopril | 76 | $399 | $5 |
| Clonidine | 13 | $172 | $13 |
| Losartan | 26 | $161 | $6 |
| Carvedilol | 26 | $161 | $6 |
| Minoxidil | 17 | $150 | $9 |
| Furosemide | 38 | $138 | $4 |
| Omeprazole | 18 | $83 | $5 |
| Famotidine | 12 | $60 | $5 |
2013: 9 drugs
| Renvela | 35 | $37,801 | $1,080 |
| Klor-Con 10 | 12 | $501 | $42 |
| Amlodipine Besylate | 54 | $332 | $6 |
| Losartan | 21 | $291 | $14 |
| Hydralazine | 13 | $152 | $12 |
| Glipizide Er | 14 | $144 | $10 |
| Lisinopril | 18 | $97 | $5 |
| Famotidine | 14 | $70 | $5 |
| Allopurinol | 15 | $69 | $5 |
Money from drug and device companies
$21,787 in 2025
| 2025 | 24 | 112 | $16,162 | $21,787 |
| 2024 | 20 | 92 | $1,600 | $3,871 |
| 2023 | 18 | 87 | $4,164 | $5,767 |
| 2022 | 13 | 68 | $19,624 | $22,621 |
| 2021 | 11 | 56 | $14,401 | $16,162 |
| 2020 | 12 | 50 | $5,018 | $6,155 |
| 2019 | 13 | 64 | $13,100 | $16,097 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Fabhalta | $8,251 | 13 payments
|
| Otsuka Pharmaceutical Development & Commercialization | None | $6,818 | 16 payments
|
| Calliditas Therapeutics US | Tarpeyo | $4,238 | 7 payments
|
| Travere Therapeutics | Filspari | $879 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $284 | 5 payments
|
| Amgen | Krystexxa | $259 | 12 payments
|
See all 111 published payments
| Novartis Pharmaceuticals | Consulting · 2025-12-23 | Fabhalta | $6,500 |
| Novartis Pharmaceuticals | Travel · 2025-12-19 | Fabhalta | $129 |
| Fresenius USA Marketing | Meals · 2025-12-19 | Velphoro | $23 |
| GlaxoSmithKline | Meals · 2025-12-18 | Benlysta | $21 |
| Apellis Pharmaceuticals | Meals · 2025-12-17 | Empaveli | $15 |
| OPKO Pharmaceuticals | Education · 2025-12-11 | Rayaldee | $18 |
| Calliditas Therapeutics US | Consulting · 2025-12-11 | Tarpeyo | $4,133 |
| Otsuka Pharmaceutical Development & Commercialization | Travel · 2025-12-10 | None | $93 |
| Otsuka Pharmaceutical Development & Commercialization | Travel · 2025-12-10 | None | $47 |
| Otsuka Pharmaceutical Development & Commercialization | Travel · 2025-12-10 | None | $77 |
| Otsuka Pharmaceutical Development & Commercialization | Consulting · 2025-12-10 | None | $2,910 |
| Otsuka Pharmaceutical Development & Commercialization | Consulting · 2025-12-10 | None | $873 |
| Otsuka Pharmaceutical Development & Commercialization | Consulting · 2025-12-10 | None | $1,746 |
| Genentech USA | Meals · 2025-12-09 | Gazyva | $30 |
| Novartis Pharmaceuticals | Travel · 2025-12-06 | Fabhalta | $323 |
| Novartis Pharmaceuticals | Travel · 2025-12-06 | Fabhalta | $350 |
| Novartis Pharmaceuticals | Meals · 2025-12-06 | Fabhalta | $199 |
| Novartis Pharmaceuticals | Travel · 2025-12-05 | Fabhalta | $484 |
| Novartis Pharmaceuticals | Meals · 2025-12-05 | Fabhalta | $142 |
| Amgen | Meals · 2025-11-24 | Tavneos | $32 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-11-15 | None | $50 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-11-15 | None | $25 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-11-15 | None | $50 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-11-15 | None | $35 |
| Otsuka Pharmaceutical Development & Commercialization | Travel · 2025-11-15 | None | $310 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-11-14 | None | $93 |
| Otsuka Pharmaceutical Development & Commercialization | Travel · 2025-11-14 | None | $277 |
| Otsuka Pharmaceutical Development & Commercialization | Travel · 2025-11-14 | None | $219 |
| Novartis Pharmaceuticals | Meals · 2025-11-12 | Fabhalta | $14 |
| Fresenius USA Marketing | Meals · 2025-11-12 | Velphoro | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-05 | Farxiga | $22 |
| Novartis Pharmaceuticals | Meals · 2025-10-31 | Fabhalta | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-28 | None | $125 |
| OPKO Pharmaceuticals | Education · 2025-10-28 | Rayaldee | $20 |
| Amgen | Meals · 2025-10-27 | Krystexxa | $21 |
| Travere Therapeutics | Meals · 2025-10-25 | Filspari | $39 |
| Travere Therapeutics | Meals · 2025-10-25 | Filspari | $40 |
| Travere Therapeutics | Meals · 2025-10-25 | Filspari | $69 |
| Travere Therapeutics | Meals · 2025-10-25 | Filspari | $85 |
| Travere Therapeutics | Meals · 2025-10-24 | Filspari | $149 |
| Travere Therapeutics | Travel · 2025-10-24 | Filspari | $209 |
| Travere Therapeutics | Travel · 2025-10-24 | Filspari | $287 |
| Mallinckrodt Hospital Products | Meals · 2025-10-15 | Acthar | $20 |
| Fresenius USA Marketing | Meals · 2025-10-15 | Velphoro | $24 |
| OPKO Pharmaceuticals | Education · 2025-10-08 | Rayaldee | $18 |
| Novo Nordisk | Meals · 2025-10-02 | Wegovy | $22 |
| Aurinia Pharma U.S. | Meals · 2025-09-27 | Lupkynis | $28 |
| Amgen | Meals · 2025-09-23 | Uplizna | $20 |
| Calliditas Therapeutics US | Meals · 2025-09-22 | Tarpeyo | $10 |
| Fresenius USA Marketing | Meals · 2025-09-15 | Velphoro | $18 |
| Amgen | Meals · 2025-09-12 | Uplizna | $10 |
| Calliditas Therapeutics US | Meals · 2025-09-12 | Tarpeyo | $19 |
| OPKO Pharmaceuticals | Education · 2025-09-11 | Rayaldee | $14 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-29 | Kerendia | $18 |
| Amgen | Meals · 2025-08-27 | Uplizna | $39 |
| Otsuka America Pharmaceutical | Meals · 2025-08-26 | Jynarque | $14 |
| Amgen | Meals · 2025-08-26 | Krystexxa | $25 |
| ANI Pharmaceuticals | Meals · 2025-08-19 | Purified Cortrophin Gel | $22 |
| Apellis Pharmaceuticals | Meals · 2025-08-15 | Empaveli | $22 |
| OPKO Pharmaceuticals | Education · 2025-08-13 | Rayaldee | $16 |
| Ardelyx | Meals · 2025-08-06 | Ibsrela | $27 |
| Fresenius USA Marketing | Meals · 2025-08-04 | Velphoro | $22 |
| Fresenius USA Marketing | Meals · 2025-08-04 | Velphoro | $1 |
| Amgen | Meals · 2025-07-29 | Krystexxa | $23 |
| Novartis Pharmaceuticals | Meals · 2025-07-25 | Fabhalta | $17 |
| Veloxis Pharmaceuticals | Meals · 2025-07-23 | Envarsus | $21 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-15 | Jardiance | $28 |
| Amgen | Meals · 2025-07-15 | Krystexxa | $9 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-09 | None | $94 |
| Alexion Pharmaceuticals | Meals · 2025-07-03 | Ultomiris | $24 |
| Mallinckrodt Hospital Products | Meals · 2025-07-02 | Acthar | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-12 | Farxiga | $23 |
| Mallinckrodt Hospital Products | Meals · 2025-06-05 | Acthar | $15 |
| GlaxoSmithKline | Meals · 2025-06-04 | Benlysta | $29 |
| Fresenius USA Marketing | Meals · 2025-06-02 | Velphoro | $23 |
| Mallinckrodt Hospital Products | Meals · 2025-05-22 | Terlivaz | $22 |
| Fresenius USA Marketing | Meals · 2025-05-21 | Velphoro | $25 |
| GlaxoSmithKline | Meals · 2025-05-19 | Benlysta | $21 |
| Calliditas Therapeutics US | Meals · 2025-05-19 | Tarpeyo | $10 |
| Novartis Pharmaceuticals | Meals · 2025-05-16 | Fabhalta | $25 |
| Novo Nordisk | Meals · 2025-05-15 | Wegovy | $18 |
| Amgen | Meals · 2025-05-08 | Tavneos | $11 |
| Novartis Pharmaceuticals | Meals · 2025-04-18 | Fabhalta | $12 |
| Mallinckrodt Hospital Products | Meals · 2025-04-15 | Acthar | $35 |
| Calliditas Therapeutics US | Meals · 2025-04-11 | Tarpeyo | $27 |
| Scpharmaceuticals | Meals · 2025-04-09 | Furoscix | $19 |
| Fresenius USA Marketing | Meals · 2025-04-08 | Velphoro | $24 |
| Novo Nordisk | Meals · 2025-04-04 | Wegovy | $16 |
| Amgen | Meals · 2025-04-01 | Krystexxa | $9 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-28 | Farxiga | $19 |
| Calliditas Therapeutics US | Meals · 2025-03-21 | Tarpeyo | $13 |
| Ardelyx | Meals · 2025-03-14 | Ibsrela | $23 |
| Lilly USA | Meals · 2025-03-13 | Jardiance | $30 |
| Mallinckrodt Hospital Products | Meals · 2025-03-07 | Acthar | $28 |
| Ardelyx | Meals · 2025-03-04 | Ibsrela | $17 |
| Novo Nordisk | Meals · 2025-03-01 | Ozempic | $18 |
| Novo Nordisk | Meals · 2025-02-26 | Ozempic | $24 |
| Novartis Pharmaceuticals | Meals · 2025-02-21 | Fabhalta | $23 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-12 | Kerendia | $14 |
| Novo Nordisk | Meals · 2025-02-11 | None | $14 |
| Mallinckrodt Hospital Products | Meals · 2025-02-11 | Acthar | $25 |
| Calliditas Therapeutics US | Meals · 2025-02-11 | Tarpeyo | $25 |
| Kyowa Kirin | Meals · 2025-02-07 | Crysvita | $15 |
| Amgen | Meals · 2025-02-03 | Krystexxa | $25 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-01-24 | None | $2 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-01-24 | None | $11 |
| OPKO Pharmaceuticals | Education · 2025-01-22 | Rayaldee | $20 |
| Amgen | Meals · 2025-01-15 | Krystexxa | $37 |
| Mallinckrodt Hospital Products | Meals · 2025-01-11 | Acthar | $21 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-08 | Jardiance | $15 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-08 | Kerendia | $21 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,871
| Amgen | Krystexxa | $2,426 | 23 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $181 | 6 payments
|
| Novartis Pharmaceuticals | Fabhalta | $167 | 8 payments
|
| Calliditas Therapeutics US | Tarpeyo | $158 | 9 payments
|
| Lilly USA | Jardiance | $136 | 6 payments
|
| Travere Therapeutics | None | $113 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $94 | 2 payments
|
| Otsuka America Pharmaceutical | Jynarque | $91 | 4 payments
|
| Fresenius USA Marketing | Velphoro | $88 | 4 payments
|
| Ardelyx | Ibsrela | $68 | 4 payments
|
| Novo Nordisk | Ozempic | $66 | 4 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $53 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $52 | 3 payments
|
| OPKO Pharmaceuticals | Rayaldee | $51 | 3 payments
|
| Mallinckrodt Hospital Products | Terlivaz | $32 | 2 payments
|
| Vifor Pharma | Veltassa | $22 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $20 | 1 payment
|
| GlaxoSmithKline | Jesduvroq | $20 | 1 payment
|
| Ultragenyx Pharmaceutical | Crysvita | $17 | 1 payment
|
| Veloxis Pharmaceuticals | Envarsus | $15 | 1 payment
|
2023: $5,767
| Bayer Healthcare Pharmaceuticals | Kerendia | $2,878 | 12 payments
|
| Vifor Pharma | Veltassa | $1,590 | 10 payments
|
| Travere Therapeutics | None | $301 | 11 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $221 | 10 payments
|
| GlaxoSmithKline | Benlysta | $142 | 8 payments
|
| Novo Nordisk | Rybelsus | $137 | 9 payments
|
| Calliditas Therapeutics US | Tarpeyo | $98 | 4 payments
|
| Genzyme | Fabrazyme | $74 | 3 payments
|
| Amgen | Tavneos | $66 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $52 | 3 payments
|
| Novartis Pharmaceuticals | None | $51 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $30 | 1 payment
|
| Ultragenyx Pharmaceutical | None | $24 | 1 payment
|
| Fresenius USA Marketing | Velphoro | $24 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $22 | 1 payment
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $21 | 1 payment
|
| Otsuka Pharmaceutical Development & Commercialization | Jynarque | $18 | 1 payment
|
| Ardelyx | Ibsrela | $17 | 1 payment
|
2022: $22,621
| Bayer HealthCare Pharmaceuticals | Kerendia | $11,066 | 16 payments
|
| Amgen | Tavneos | $9,231 | 12 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $1,887 | 10 payments
|
| Mallinckrodt Hospital Products | Acthar | $96 | 2 payments
|
| GlaxoSmithKline | Benlysta | $70 | 3 payments
|
| Horizon Therapeutics plc | Krystexxa | $66 | 4 payments
|
| Vifor Pharma | Veltassa | $62 | 3 payments
|
| Otsuka America Pharmaceutical | Jynarque | $51 | 3 payments
|
| Calliditas Therapeutics US | Tarpeyo | $22 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $18 | 1 payment
|
| Novo Nordisk | Rybelsus | $18 | 1 payment
|
| Fresenius USA Marketing | Velphoro | $17 | 1 payment
|
| Travere Therapeutics | None | $17 | 1 payment
|
2021: $16,162
| AstraZeneca Pharmaceuticals LP | Lokelma | $7,281 | 21 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $6,442 | 10 payments
|
| Vifor Pharma | Veltassa | $2,006 | 3 payments
|
| OPKO Pharmaceuticals | Rayaldee | $98 | 6 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $97 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $71 | 4 payments
|
| Daiichi Sankyo | Injectafer | $44 | 2 payments
|
| Fresenius USA Marketing | Velphoro | $40 | 2 payments
|
| GlaxoSmithKline | Benlysta | $34 | 2 payments
|
| Amgen | Parsabiv | $33 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $15 | 1 payment
|
2020: $6,155
| AstraZeneca Pharmaceuticals LP | Lokelma | $3,428 | 18 payments
|
| Relypsa | Veltassa | $1,499 | 6 payments
|
| Otsuka Pharmaceutical Development & Commercialization | Jynarque | $718 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $145 | 2 payments
|
| Akebia Therapeutics | Auryxia | $109 | 4 payments
|
| OPKO Pharmaceuticals | Rayaldee | $70 | 4 payments
|
| Otsuka America Pharmaceutical | Jynarque | $69 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $31 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $31 | 2 payments
|
| GlaxoSmithKline | Benlysta | $24 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $16 | 1 payment
|
| Daiichi Sankyo | Injectafer | $15 | 1 payment
|
2019: $16,097
| Relypsa | Veltassa | $9,981 | 22 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $5,506 | 17 payments
|
| Baxter Healthcare | Renal - Pd | $136 | 1 payment
|
| Bard Peripheral Vascular | None | $135 | 1 payment
|
| Fresenius USA Marketing | Velphoro | $72 | 4 payments
|
| Otsuka America Pharmaceutical | Jynarque | $54 | 3 payments
|
| Daiichi Sankyo | Injectafer | $46 | 3 payments
|
| Genzyme | Fabry-Disease | $37 | 2 payments
|
| Amgen | Parsabiv | $37 | 2 payments
|
| OPKO Pharmaceuticals | Rayaldee | $30 | 2 payments
|
| Alexion Pharmaceuticals | Soliris | $24 | 2 payments
|
| Mallinckrodt Enterprises | Acthar | $21 | 1 payment
|
| Retrophin | (815) Thiola | $18 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AstraZeneca Pharmaceuticals LP · A Phase III,Randomised,Double Blind,Placebo Controlled,Event Driven Study To Assess the Efficacy,Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure · 2025 | Their institution | $125,362 |
| AstraZeneca Pharmaceuticals LP · A Phase 3,Randomised,Double Blind,Active Controlled Study To Assess the Efficacy,Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease Ckd Progression in Participants With Ckd and High Blood Pressure · 2025 | Their institution | $119,056 |
| VERTEX PHARMACEUTICALS INCORPORATED · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (Rainier) · 2025 | Their institution | $83,778 |
| AstraZeneca Pharmaceuticals LP · A Phase 3,Randomised,Double Blind,Active Controlled Study To Assess the Efficacy,Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease Ckd Progression in Participants With Ckd and High Blood Pressure · 2024 | Their institution | $26,071 |
Professional record
- NPI
- 1609067537
- Licence
- CA A118650, MA 232797California A118650: Current · expires 2027-09-30
- Group
- West Coast Kidney
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X); Internal medicine (207R00000X)
- Mailing address
- 1999 Mowry Ave, Suite R, Fremont, CA, 94538
- NPI first listed
- 2007-08-06
- NPI last updated
- 2016-09-12
This is when the NPI record was last certified, not a medical board exam.